![Acceleron's ACE-083 could succeed in muscle growth but long-term functional benefit may be limited | by Richardwilliam | Medium Acceleron's ACE-083 could succeed in muscle growth but long-term functional benefit may be limited | by Richardwilliam | Medium](https://miro.medium.com/v2/resize:fit:768/1*CJ92SiHwC6BwcruqqDpYNg.png)
Acceleron's ACE-083 could succeed in muscle growth but long-term functional benefit may be limited | by Richardwilliam | Medium
![Local administration of ACE-083 in wild-type mice causes dose-dependent... | Download Scientific Diagram Local administration of ACE-083 in wild-type mice causes dose-dependent... | Download Scientific Diagram](https://www.researchgate.net/publication/335000117/figure/fig1/AS:788899634872326@1565099738797/Local-administration-of-ACE-083-in-wild-type-mice-causes-dose-dependent-growth-of-the.png)
Local administration of ACE-083 in wild-type mice causes dose-dependent... | Download Scientific Diagram
![Acceleron Receives FDA Fast Track Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy (FSHD) - Drug Discovery and Development Acceleron Receives FDA Fast Track Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy (FSHD) - Drug Discovery and Development](https://drugdiscoverytrends.com/wp-content/uploads/2019/10/180504-acceleron.jpg)
Acceleron Receives FDA Fast Track Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy (FSHD) - Drug Discovery and Development
![Randomized phase 2 study of ACE‐083, a muscle‐promoting agent, in facioscapulohumeral muscular dystrophy - Statland - 2022 - Muscle & Nerve - Wiley Online Library Randomized phase 2 study of ACE‐083, a muscle‐promoting agent, in facioscapulohumeral muscular dystrophy - Statland - 2022 - Muscle & Nerve - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/a5d7d5ba-a281-48b2-825a-579aa3223451/mus27558-fig-0003-m.jpg)
Randomized phase 2 study of ACE‐083, a muscle‐promoting agent, in facioscapulohumeral muscular dystrophy - Statland - 2022 - Muscle & Nerve - Wiley Online Library
![Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease | Scientific Reports Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-019-47818-w/MediaObjects/41598_2019_47818_Fig3_HTML.png)
Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease | Scientific Reports
![MAESTrO: Acceleron receives FDA fast track designation for ACE-083 in facioscapulohumeral muscular dystrophy MAESTrO: Acceleron receives FDA fast track designation for ACE-083 in facioscapulohumeral muscular dystrophy](https://s3-ap-southeast-2.amazonaws.com/cdn.maestrodatabase.com/525c9929-4037-4647-923a-baba93c495d6.png)
MAESTrO: Acceleron receives FDA fast track designation for ACE-083 in facioscapulohumeral muscular dystrophy
![The Stumbling Blocks Of Celgene-Dependent Acceleron And Why You Should Hedge Your Bets (NYSE:MRK) | Seeking Alpha The Stumbling Blocks Of Celgene-Dependent Acceleron And Why You Should Hedge Your Bets (NYSE:MRK) | Seeking Alpha](https://static.seekingalpha.com/uploads/2017/11/6/21405941-15099932742419074_origin.png)
The Stumbling Blocks Of Celgene-Dependent Acceleron And Why You Should Hedge Your Bets (NYSE:MRK) | Seeking Alpha
![FDA Grants Orphan Drug Designation to Acceleron Pharma's ACE-083 Muscle Growth Drug for Charcot-Marie-Tooth Disease - Quest | Muscular Dystrophy Association FDA Grants Orphan Drug Designation to Acceleron Pharma's ACE-083 Muscle Growth Drug for Charcot-Marie-Tooth Disease - Quest | Muscular Dystrophy Association](https://mdaquest.org/wp-content/uploads/2022/05/iStock-916966528-18-scaled-e1652326047635.jpg)
FDA Grants Orphan Drug Designation to Acceleron Pharma's ACE-083 Muscle Growth Drug for Charcot-Marie-Tooth Disease - Quest | Muscular Dystrophy Association
![Acceleron Announces ACE-083 Phase 2 Trial Presentation at the American Academy of Neurology 70th Annual Meeting | Business Wire Acceleron Announces ACE-083 Phase 2 Trial Presentation at the American Academy of Neurology 70th Annual Meeting | Business Wire](https://mms.businesswire.com/media/20180426005535/en/582919/23/acceleron_logo.jpg)